NCT04781192View on ClinicalTrials.gov

The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Biliary Tract Cancer
Interventions
DRUG

Durvalumab

Intra-Venous(IV) once every 28 days (approximately every 4 weeks \[q4w\])

DRUG

Regorafenib

Oral once per day, Days 1 - 21 every 28 days

Trial Locations (5)

64064

RECRUITING

University of Kansas Cancer Center - Lee's Summit, Lee's Summit

64116

RECRUITING

The University of Kansas Medical Center, North Kansas City

64154

RECRUITING

University of Kansas Cancer Center - North, Kansas City

66205

RECRUITING

The University of Kansas Medical Center, Westwood

66210

RECRUITING

University of Kansas Cancer Center - Overland Park, Overland Park

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER